"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”
A trial of mitozantrone or docetaxel chemotherapy for advanced prostate cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial was looking at chemotherapy for prostate cancer that had spread and was no longer responding to hormone therapy.
The trial compared 2 different ways of giving the chemotherapy drug docetaxel with another chemotherapy drug, mitoxantrone.
Summary of results
The trial team found that having docetaxel was better than mitoxantrone for men with advanced prostate cancer.
This trial recruited 1,006 men. They were put in to 1 of 3 treatment groups
- 335 had docetaxel every 3 weeks
- 334 had docetaxel once a week
- 337 had mitoxantrone once a week
The researchers looked at how well the men’s pain was controlled, their quality of life, their PSA blood level and how long they lived for. In all cases those who had docetaxel had better results than those who had mitoxantrone.
For the men having docetaxel every 3 weeks the results were
- 73 (22%) reported improved quality of life
- 150 (45%) reported better pain control
- 117 (35%) their PSA blood level had halved
For the men having docetaxel once a week
- 76 (23%) reported improved quality of life
- 160 (48%) reported better pain control
- 103 (31%) their PSA blood level had halved
For the men having mitoxantrone
- 43 (13%) reported improved quality of life
- 107 (32%) reported better pain control
- 74 (22%) their PSA blood level had halved
On average, men in both of the docetaxel groups lived longer than the men in the mitoxantrone group. And the men who had docetaxel every 3 weeks on average lived the longest.
The researchers concluded that treatment with docetaxel every 3 weeks was much better for men with advanced prostate cancer than mitoxantrone.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Nick James